NXP800

NXP800 (CCT361814) is a potent and orally active heat shock factor 1 (HSF1) pathway inhibitor. NXP800 has the potential for cancer research[1][2].

Product Specifications

CAS Number

[1693734-80-3]

Product Name Alternative

CCT361814

UNSPSC

12352005

Target

HSP

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/nxp800.html

Purity

99.86

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=CC=C2OCCOC2=C1)NC3=CC=C(C(NC(C4=CC5=C(N=C(CN6CCN(CC6)CC)C=C5)C=C4)=O)=C3)F

Molecular Formula

C32H32FN5O4

Molecular Weight

569.63

References & Citations

[1]Keith Jones, et al. Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1. WO2015049535A1.|[2]Pasqua AE, et al. HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies. J Med Chem. 2023